Letybo (Botulinum Toxin Type A)

Botulinum toxin type A cleaves the SNAP‑25 protein, which is essential for the release of acetylcholine at the neuromuscular junction. By blocking this neurotransmitter, the toxin prevents muscle contraction in the targeted area, leading to temporary paralysis and reduction of abnormal muscle activity.

The dose of Letybo is individualized by the prescribing clinician based on the specific indication, severity of symptoms, and patient characteristics. The prescriber determines the appropriate amount, injection sites, and treatment intervals according to clinical guidelines and product labeling.

Safety data for Letybo in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and breastfeeding mothers should consider the unknown excretion into milk and discuss alternatives with their healthcare provider.

To request Letybo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Letybo contains botulinum toxin type A, the same active molecule found in other branded products such as Botox® and Dysport®. While the core mechanism is identical, differences may exist in formulation, unit potency, and approved indications. Clinical choice often depends on physician experience, regulatory approvals, and specific patient needs.

Letybo must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product. Proper cold‑chain handling ensures stability and maintains efficacy until the point of use.

Letybo is delivered by a qualified healthcare professional via intramuscular injection. The clinician selects appropriate injection sites based on the targeted muscle group, uses a sterile technique, and may employ electromyographic or anatomical guidance to ensure accurate placement.

Serious risks include dysphagia, respiratory compromise, generalized muscle weakness resembling botulism, vision changes, and severe allergic reactions such as anaphylaxis. Prompt recognition and medical intervention are essential if any of these symptoms develop after treatment.

Letybo is contraindicated in individuals with a known hypersensitivity to botulinum toxin type A or any of its excipients, and in patients with active infection at the intended injection site. Caution is also advised for those taking medications that affect neuromuscular transmission or with conditions that could exacerbate toxin spread.